Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06625671 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE Participants
A Phase 1 study of Systemic Lupus Erythematosus (SLE), sponsored by DualityBio.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 148
- Enrollment target
- 4
- Study locations
NCT06625671: Recruiting Phase 1 study of Systemic Lupus Erythematosus (SLE), sponsored by DualityBio.
NCT06625671 is a Phase 1 study of Systemic Lupus Erythematosus (SLE) that is actively recruiting participants, run by DualityBio. The registered enrollment target is 148 participants, below the 1,054-participant average among 14 other Systemic Lupus Erythematosus (SLE) trials with a reported enrollment target (86% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06625671, a Phase 1 study of Systemic Lupus Erythematosus (SLE), is actively recruiting participants, sponsored by DualityBio.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 148 participants
- Enrollment target
- 4
- Study locations
Study Summary
A Phase 1/2a Study of DB-2304 in Healthy Participants and Participants with Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus
Primary Outcome
Treatment-emergent adverse events
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Prednisone
- DRUG DB-2304
Study Locations (4)
Texas
- US04-0 - Irving
- US02-0 - San Antonio
Florida
- US03-0 - Clearwater
Victoria
- Site AUS01-0 - Melbourne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 148 participants |
| Start Date | 2024-10-04 |
| Est. Completion | 2026-06-05 |
| Phase | Phase 1 |
What NCT06625671 shows while recruiting
NCT06625671 is an interventional study that assigns participants to a tested intervention. The registered 148 participants enrollment target is mid-sized for trials with a published cap, below the 1,054-participant average among 14 other Systemic Lupus Erythematosus (SLE) trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Systemic Lupus Erythematosus (SLE) appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06625671 reports a single indexed study location in Texas, Florida, Victoria.
Frequently Asked Questions
What is clinical trial NCT06625671 about?
NCT06625671 is a clinical study titled "A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE Participants". A Phase 1/2a Study of DB-2304 in Healthy Participants and Participants with Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus
What is the current status of trial NCT06625671?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 148 participants. The study started on 2024-10-04. Estimated completion is 2026-06-05.
What conditions does trial NCT06625671 study?
This clinical trial studies the following conditions: Systemic Lupus Erythematosus (SLE).
What interventions are being tested in trial NCT06625671?
The interventions under investigation include: Placebo (DRUG), Prednisone (DRUG), DB-2304 (DRUG).
Who is sponsoring clinical trial NCT06625671?
This trial is sponsored by DualityBio, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06625671 being conducted?
This trial has 4 study locations across Florida, Texas, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Systemic Lupus Erythematosus (SLE)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06625671's enrollment target sits among peer trials
148 7th of 14 higher than 8 of 14 other Systemic Lupus Erythematosus (SLE) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Systemic Lupus Erythematosus (SLE) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus
RECRUITING · Phase 1
-
A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
RECRUITING · Phase 1
-
UC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) Patients
RECRUITING · Phase 1
-
Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus
RECRUITING · Phase 1
-
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
RECRUITING
-
Research Accelerated by You Lupus Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00739362 · 148 participants · Phase 2
Effects of Brain Stimulation on Food Intake and Behavioral Weight Loss Treatment
- NCT03161223 · 148 participants · Phase 1
Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma
- NCT03858231 · 148 participants · Phase 4
Opioids Versus Non-Opioids Postoperative After Knee Arthroscopic Surgery
- NCT04486352 · 148 participants · Phase 1
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI